An insulin injection can manage diabetes symptoms, but actually curing the disease would mean healing cells in the pancreas that produce insulin, a hormone that regulates the amount of sugar in blood.
One promising approach may be to stimulate the regeneration of those cells with drugs. But there's a major obstacle: The growth triggered by the drug is willy-nilly, affecting tissues not just in the pancreas but throughout the body.
Now, a team of Stanford University endocrinologists and chemists has taken a step toward targeting the right cells more precisely, using a property that researchers have long known about but never exploited for treatment: Beta cells, the insulin-producing cells in the pancreas, have a particularly strong taste for zinc.
In a study to be published online Dec. 6 in Cell Chemical Biology, Stanford researchers used that fact to selectively deliver a drug to beta cells. Justin Annes, MD, PhD, assistant professor of medicine, is the senior author. Graduate student Timothy Horton is the lead author.
The method hasn't been optimized yet, and it isn't anywhere near ready for clinical use. "We're at the earliest stages," Annes said. But in a field where the main options are insulin injections and insulin pumps, which continuously deliver the hormone through a catheter, it could pave the way to more appealing alternatives.
Diabetes is a disease in which the body can't produce enough insulin to maintain normal blood sugar levels. For years, Annes' goal has been to develop a medication that would promote the regeneration of insulin-producing beta cells. Although some researchers deemed that impossible, Annes and his colleagues recently succeeded in creating specific molecules that make beta cells divide and produce more beta cells.
That advance might have given new hope to diabetes patients, but there was a catch: The way to get beta cells to start dividing and replicating is the same way to get lots of other cells to divide and replicate. In other words, researchers might be able boost the number of beta cells in the pancreas, but in the process they'd get lots of other cell types to replicate as well. The result would be uncontrolled, untargeted replication that would affect lots of other organs beside the pancreas, most likely for the worse.
Then Annes had a thought: Researchers have known since the 1940s that beta cells collect about 1,000 times more zinc than surrounding tissue cells. Researchers have mostly used that fact as a way to stain and visually identify beta cells in pancreatic tissue samples. But Annes reasoned that if he could somehow get a regenerative drug to seek out zinc, he could get it to beta cells.
Call in the chemists
"The only problem was, I didn't know how to generate compounds that could test this hypothesis," Annes said. So he turned to Horton, a graduate student in chemistry, and Mark Smith, a senior research scientist at Stanford ChEM-H and director of its Medicinal Chemistry Knowledge Center.
Together, they devised a strategy based on chelation, a standard technique in chemistry that's perhaps best known in medicine as a treatment for lead and mercury poisoning. In such cases, doctors administer a drug that forms tight bonds with the metals, which can then be flushed out of the body.
Annes, Horton and Smith aimed to use a zinc-chelating agent, which will bond to zinc wherever it runs into it, to deliver a drug to zinc-loving cells, but first they needed to see whether the chelating agent itself would accumulate in beta cells. After initial lab tests showed it did, they attached a beta-cell regenerating drug to the zinc-chelating agent, and found that the drug would also build up in beta cells in a lab dish.
The team also showed that its zinc-chelation approach amassed more of the drug in beta cells than other cell types. When the drug was administered to rat cells, including beta cells, in a dish, the beta cells regenerated about 250 percent more than other cell types. The effect was smaller but still present in human cells in a dish: Beta cells replicated about 130 percent more than nonbeta cells over the course of the experiment.
That's not to say that a treatment is around the corner, the researchers caution. "This is the first demonstration of a selectively delivered replication molecule in beta cells," Annes said, and "it's not sufficient for therapeutic applications." But the team believes the approach could one day lead to treatments if they can improve its beta-cell selectivity.
Annes is a member of Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the Stanford Cancer Institute and Stanford ChEM-H.
Other Stanford authors are Smith; postdoctoral scholars Paul Allegretti, PhD, and Sooyeon Lee, PhD; and graduate student Hannah Moeller.
The study was funded by the ChEM-H Chemistry/Biology Interface Predoctoral Training Program, Stanford Bio-X, a Stanford interdisciplinary graduate fellowship, the Friedenrich Diabetes Fund and the National Institutes of Health (grants T32DK007217, T32GM113854, UL1TR001085, R01DK101530 and P30DK116074).
Stanford's departments of Medicine and of Chemistry also supported the work.
The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.